5 chapters across the catalog
New reports indicate that users of weight-loss drugs like Ozempic are experiencing significant hair loss due to metabolic stress. This condition, known as telogen effluvium, occurs when the body enters survival mode after rapid weight loss. Other documented side effects include stomach paralysis and permanent digestive issues, leading many users to quit the drugs within a year.
RFK Jr., Weight Stigma Czar, Big Pharma GLP-1
San Francisco has appointed a "weight stigma czar" to promote fat activism, a move the host criticizes as anti-science and harmful to public health. Meanwhile, the FDA is accused of protecting Big Pharma interests by cracking down on low-cost compounded GLP-1 peptides, forcing patients toward expensive patented drugs. The host expresses hope that RFK Jr. will address these issues of government-promoted unhealthiness and pharmaceutical lobbying.
Preventative Medicine, GLP-1 Drugs and Food Additives
The discussion covers the rise of metabolic disease and the use of GLP-1 drugs as a "tool" that is often mismanaged. Bueller notes that while the U.S. allows 10,000 ingredients in food, many are banned in Europe. Chemicals like glyphosate (Roundup) and atrazine are linked to cancer and endocrine disruption, yet they remain prevalent in the American food supply due to the FDA's reliance on industry-funded data.
GLP-1 Drugs, Microplastics in the Brain, and Kellogg's Petitions
A recent Harvard study revealed that microplastics now account for 5% of human brain weight in America. Amidst this environmental crisis, there is a push to put children on GLP-1 weight loss drugs rather than addressing the toxic food supply. Activists recently marched on Kellogg's headquarters with hundreds of thousands of signatures demanding the company remove harmful dyes and chemicals from American products, a request the company reportedly refused.
FDA Funding, Compounding Pharmacy Battles, and HIV Drug History
Big Pharma provides 50% of the FDA's funding, leading to regulatory decisions that favor major manufacturers over compounding pharmacies. Eli Lilly and Novo Nordisk are currently lobbying the FDA to ban the compounding of GLP-1 weight loss drugs despite ongoing national shortages. This mirrors a 1980s tactic where pharmaceutical companies sued generic manufacturers to prevent affordable HIV treatments from reaching patients in Africa.
